Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EPS (Weighted Average and Diluted): 2014-2025

Historic EPS (Weighted Average and Diluted) for Ascendis Pharma A (ASND) over the last 8 years, with Sep 2025 value amounting to $1.17.

  • Ascendis Pharma A's EPS (Weighted Average and Diluted) fell 38.11% to $1.17 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.44, marking a year-over-year decrease of 47.26%. This contributed to the annual value of -$7.07 for FY2024, which is 23.17% up from last year.
  • Ascendis Pharma A's EPS (Weighted Average and Diluted) amounted to $1.17 in Q3 2025, which was up 25.95% from $0.93 recorded in Q2 2025.
  • Ascendis Pharma A's EPS (Weighted Average and Diluted)'s 5-year high stood at $3.14 during Q3 2023, with a 5-year trough of -$17.45 in Q4 2022.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was $1.89 (2024), whereas its average is $1.86.
  • Per our database at Business Quant, Ascendis Pharma A's EPS (Weighted Average and Diluted) surged by 109.50% in 2023 and then tumbled by 61.00% in 2025.
  • Ascendis Pharma A's EPS (Weighted Average and Diluted) (Quarterly) stood at -$14.97 in 2021, then fell by 16.54% to -$17.45 in 2022, then surged by 109.50% to $1.66 in 2023, then plummeted by 58.73% to $0.68 in 2024, then tumbled by 38.11% to $1.17 in 2025.
  • Its last three reported values are $1.17 in Q3 2025, $0.93 for Q2 2025, and $1.66 during Q1 2025.